EISAI’S breakthrough therapy for Alzheimer’s disease has been cleared by regulators in China, giving the drugmaker a chance to tap growing demand for medicines to treat the debilitating condition in a rapidly aging population.
EISAI’S breakthrough therapy for Alzheimer’s disease has been cleared by regulators in China, giving the drugmaker a chance to tap growing demand for medicines to treat the debilitating condition in a rapidly aging population.